Gliomas News and Research

RSS

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

Researchers develop software tools to search and compare patient data at hospitals across Europe

By matching children with rare or life-threatening diseases and modelling potential disease progression, researchers hope to find new routes forward.

16 Nov 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

19 Oct 2009

Physical activity during adolescence decreases risk of glioma

While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height.

7 Oct 2009

Research study reveals primary chemotherapy benefits

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

3 Oct 2009

Burzynski Research Institute and BBSF sign Research Agreement

The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management support for BRI’s ongoing Phase II and Phase III protocol studies of Antineoplaston (ANP) treatment for gliomas.

30 Sep 2009

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma.

14 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Altered gene network interaction plays an important role in brain tumors

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

1 Sep 2009

Discovery of new gene mutations linked to leukemia

Decoding the complete DNA of cancer patients is giving scientists at Washington University School of Medicine in St. Louis a clearer picture of the complexity of the disease and allowing them to see intriguing and unexpected genetic relationships among patients.

5 Aug 2009

$Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma$

Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma

Hypofractionated stereotactic radiotherapy was well-tolerated and improved symptoms in patients with recurrent low-grade glioma, according to researchers from the Kimmel Cancer Center at Jefferson.

22 Apr 2009

New drug to target tumor cells and blood vessels

Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

21 Apr 2009

New drug to target tumor cells and blood vessels

21 Apr 2009

New imaging analysis method predicts brain tumor survival

As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found.

20 Apr 2009

3 events offer hope for people with brain tumors

People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.

16 Apr 2009

Scientists show how gene alteration can lead to the development of a type of brain cancer

An international team of scientists from the Moores Cancer Center at the University of California, San Diego, the University of North Carolina and several institutions in China have explained how a gene alteration can lead to the development of a type of brain cancer, and they have identified a compound that could staunch the cancer's growth.

14 Apr 2009

Discovery of chemical compound that may stop deadly brain tumors

Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.

12 Apr 2009

Discovery of compound that may stop glioblastoma multiforme

12 Apr 2009

Gliomas News and Research

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

Researchers develop software tools to search and compare patient data at hospitals across Europe

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Physical activity during adolescence decreases risk of glioma

Research study reveals primary chemotherapy benefits

Burzynski Research Institute and BBSF sign Research Agreement

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Altered gene network interaction plays an important role in brain tumors

Discovery of new gene mutations linked to leukemia

Hypofractionated stereotactic radiotherapy beneficial for recurrent low-grade glioma

New drug to target tumor cells and blood vessels

New drug to target tumor cells and blood vessels

New imaging analysis method predicts brain tumor survival

3 events offer hope for people with brain tumors

Scientists show how gene alteration can lead to the development of a type of brain cancer

Discovery of chemical compound that may stop deadly brain tumors

Discovery of compound that may stop glioblastoma multiforme

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News